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Abstract Recombinant TNF-related apoptosis-inducing
ligand (TRAIL) is considered a powerful and selective
inducer of tumor cell death. We hypothesize that TRAIL’s
potential as anticancer agent can be enhanced further by
promoting its accumulation in tumor tissue. For this pur-
pose, we developed TRAIL complexes that bind to
angiogenic endothelial cells. We employed an avidin–
biotin pretargeting approach, in which biotinylated TRAIL
interacted with RGD-equipped avidin. The assembled
complexes killed tumor cells (Jurkat T cells) via apoptosis
induction. Furthermore, we demonstrated that the associa-
tion of the RGD-avidin-TRAIL complex onto endothelial
cells enhanced the tumor cell killing activity. Endothelial
cells were not killed by TRAIL nor its derived complexes.
Our approach can facilitate the enrichment of TRAIL onto
angiogenic blood vessels, which may enhance intratumoral
accumulation. Furthermore, it offers a versatile technology
for the complexation of targeting ligands with therapeutic
recombinant proteins and by this a novel way to enhance
their speciﬁcity and activity.
Keywords Apoptosis  Angiogenesis  Drug targeting 
Therapeutic proteins
Introduction
TNF ligands have strong potential as anti-tumor agents,
acting in different ways on either tumor cells or tumor
vasculature, or by promoting the induction of tumor-
directed immune responses [1]. The broad clinical use of
TNF ligands is prohibited however due to lack of tumor
selectivity, causing various side effects. A recently identi-
ﬁed TNF family member is TNF related apoptosis-inducing
ligand (TRAIL) [2]. Many tumor types are sensitive to
TRAIL or become sensitive after treatment with chemo-
therapeutic drugs [3]. Soluble TRAIL variants showed no
cytotoxic effects on most primary human cells and were
well tolerated in mice and chimpanzees [4, 5]. However,
the selectivity of TRAIL for tumor cells over normal cells
is lost when TRAIL forms multimeric complexes. For
example, it has been observed that cross-linked TRAIL
induces apoptosis more efﬁciently than non-aggregated
trimeric TRAIL [6], but such cross-linked TRAIL also
caused cell death in normal hepatic cells [7]. It seems
therefore attractive to design clustered TRAIL variants
with enhanced speciﬁcity for tumor tissue. The increased
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counterbalance or prevent side effects elsewhere in the
body. In the present paper, we investigated the develop-
ment of TRAIL complexes equipped with targeting ligands
directed to the tumor vasculature. Enhanced retention of
TRAIL complexes at the tumor vasculature will enhance
their accumulation in the tumor tissue, thereby favoring the
desired therapeutic activity and reducing potential toxicity.
Several recent papers described the development of
recombinant TNF family members with enhanced target
speciﬁcity. One approach is to modify the intrinsic speci-
ﬁcity of TRAIL for its target Death-receptor 5 speciﬁc by
substituting amino-acids located in the receptor binding
interface of TRAIL [8]. Development of chimaeras is
another successful approach. Linkage of TRAIL to scFv
antibody fragments yielded constructs which bind to
additional surface-exposed receptors on tumor cell types
[9–11]. Similarly, other TNF family members like Fas-
ligand and TNFa (have been conjugated to tumor-cell
directed targeting ligands, yielding chimeric proteins with
full or even enhanced therapeutic activity [11–15].
Although the recombinant approach has been applied
successfully for the production of chimeric proteins, low
production yields may hamper the feasibility of such a
strategy. Especially when multiple targeting ligands are
introduced into a protein subunit, which is preferred for
high avidity binding, aberrant folding of chimeric proteins
can occur. In the current study we therefore pursued a
chemical approach, in which TRAIL was biotinylated and
complexed to avidin equipped with multiple targeting
ligands. Avidin–biotin complexation is a widely accepted
approach in diagnostic applications that employ immuno-
detection steps, and is also considered an attractive strategy
for the preparation of tumor targeted complexes, especially
in so-called pretargeting approaches in which the com-
plexes are assembled in vivo at the cell surface of tumor
cells. Commonly, such strategies employ biotinylated
tumor-speciﬁc antibodies and a therapeutic or diagnostic
cargo coupled to avidin [16, 17].
The approach presented in this paper differs to the
above-discussed strategies in several aspects. First, we now
equipped TRAIL with targeting ligands directed to angio-
genic endothelium rather than to tumor cells, allowing an
enhanced binding to the tumor blood vessels. The vascular
wall is in direct contact with the systemic circulation,
which makes it an easily attainable target for therapeutic
proteins. Furthermore, intratumoral pressure, which ham-
pers the penetration of macromolecules into tumor tissue
will not affect the homing to of RGD-equipped complexes
to the angiogenic endothelium.
Second, we have prepared a different type of targeted
avidin that can interact directly via covalently attached
RGD-groups with tumor endothelial cells. Thus, the
developed avidin–biotin-TRAIL complexes will home to
angiogenic endothelium without the need of complexation
with a biotinylated antibody, thereby leaving its biotin-
binding sites available for complexation with the biotin-
ylated TRAIL. The functionalization of avidin with
RGD-homing ligands was carried out using a cyclic
RGD-peptide with high afﬁnity and speciﬁcity for avb3
integrin on angiogenic endothelium [18]. We furthermore
applied a polyethylenglycol (PEG) linker for coupling of
the RGD-ligand, which brings several advantages, such as
a reduced non-speciﬁc binding of the avidin and reduced
immunogenicity [19]. The now developed RGDPEG-
avidin conjugates contain the RGD homing ligand attached
to the distal end of the PEG groups.
In order to minimize loss of functional TRAIL activity,
we have compared two different biotinylation strategies
that react at different functional groups in the protein. We
used a conventional Biotin-NHS reagent that binds to pri-
mary amino groups in the protein, and we employed the
Biotin-ULS (ULS: universal linkage system) reagent,
which reacts at methionine residues. Figure 1 shows a
schematic representation of the developed complexes and
their interaction with target cells. The products were
evaluated for their association with avb3 integrin express-
ing endothelial cells and for their antitumor activity in both
endothelium and cultured tumor cells. Our results demon-
strate that recombinant TRAIL can be complexed with
endothelial speciﬁc targeting ligands in such a way that it
maintains its extensive cell killing activity either in solu-
tion or when displayed on the surface of endothelial cells.
TRAIL
RGD
RGD
avidin
+
induction of apoptosis
via  Death Receptors
binding to tumor blood
vessels
via αvβ3 integrin
biotin PEG
RGDPEG-avidin biotinylated
TRAIL
Fig. 1 Schematic representation of RGD-avidin:TRAIL complexes.
Soluble recombinant human TRAIL was modiﬁed with biotin groups
via two different reagents that either react at lysine or methionine
residues. Biotinylated TRAIL was complexed to an avidin-based
targeting device equipped with approximately 5 RGD-peptide ligands
per avidin molecule. A hydrophilic PEG-linker was used to append
the RGD-peptides to avidin. The assembled complexes can bind to
tumor blood vessels via RGD//avb3-integrin interactions, while
apoptosis can be induced via TRAIL/DR ligation
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Preparation and characterization of RGDPEG-avidin
Avidin was modiﬁed with heterobifunctional PEG groups
that can react with primary amino groups in avidin, after
which RGD-peptide groups can be conjugated to their
distal ends. The hydrophilic PEG groups of 3.4 kDa will
furthermore reduce non-speciﬁc protein interactions.
Brieﬂy, avidin (2 mg, 32 nmol, Sigma) was dissolved in
PBS at 10 mg/ml and treated with a 50-fold molar excess of
the heterobifunctional vinylsulfone-polyethylenglycol-N-
hydroxysuccinimide ester (1 mg, 292 nmol, VNS-PEG-
NHS; Nektar, Alabama, USA), which had been dissolved in
water at a concentration of 20 mg/ml. The PEG linker was
added drop wise. The reaction mixture was protected from
light with tin foil and incubated for 1 h at room temperature
on a spiramix rollerbank. Meanwhile, the RGD peptide
c(RGDf(e-S-acetylthioacetyl)K) (Ansynth Service, Roose-
ndaal, The Netherlands) was dissolved at 10 mg/ml in a 1:4
acetonitrile/water mixture. The peptide was added drop
wise to the reaction mixture at a molar ratio of 55:1, after
which freshly prepared hydroxylamine was added to a ﬁnal
concentration of 50 mM. The reaction was carried out
overnight at room temperature while protected from light.
Remaining VNS groups were quenched by addition of
cysteine (55:1 molar excess over the amount of avidin),
after which the product was puriﬁed by size exclusion
chromatography on a Highload superdex 200 column
(Amersham Biosciences), pre-equilibrated in PBS. The
ﬁnal product RGDPEG-avidin was stored in PBS at -20C.
RGDPEG-avidin conjugates were characterized for
protein content by BCA protein assay (Pierce). Coupling of
RGDPEG groups to avidin was demonstrated by SDS-
PAGE performed on a mini-Protean II system (Bio-Rad)
using 12% Ready Gels (Bio-Rad, The Netherlands).
Duplicate gels were either stained for protein (Coomassie
Brilliant Blue staining) or blotted on a PVDF membrane
(Roche, Mannheim, Germany). The membrane was
blocked with BSA and subsequently incubated with an
in-house raised anti-RGD polyclonal rabbit antiserum
speciﬁc for the conjugated RGD-peptide [20]. Blots
were further developed with goat-anti-rabbit peroxidase
(GARPO)/DAB detection. The grade of RGD-pegylation
was furthermore determined by MALDI-TOF analysis as
described previously [21].
Expression and puriﬁcation of recombinant human
His-tagged TRAIL
A cDNA corresponding to human soluble TRAIL (amino
acids 114–281) was cloned downstream of the
hexahistidine (His) tag sequence in pET15B (Novagen)
using NdeI and BamHI restriction sites. Escherichia coli
BL21 (DE3) (Invitrogen) was subsequently transformed
with the His-TRAIL construct. The transformed host was
grown in shake ﬂasks at four liter scale as described pre-
viously [22]. The culture was centrifuged at 2,500 rpm and
the supernatant was discarded. The isolated pellet was
resuspended in three volumes of extraction buffer (20 mM
phosphate buffer pH 8 containing 200 mM NaCl, 10% (v/
v) glycerol and 7 mM b-mercaptoethanol).
Cells were disrupted using sonication and extracts were
clariﬁed by centrifugation at 40,000 g. Subsequently, the
supernatant was loaded on a cobalt-charged IMAC
TALON column (Clontech) and His-TRAIL was eluted
with a step gradient of extraction buffer containing 0.5 M
imidazole. Trimeric His-TRAIL was puriﬁed by size-
exclusion chromatography on a Hiload Superdex 75 col-
umn (Amersham Biosciences), to remove impurities. The
ﬁnal product was ﬂash frozen and stored at -80Ci n
storage buffer (phosphate buffer pH 7.4 containing
150 mM NaCl, 3.5 mM DTT and 20 lM ZnSO4). Puriﬁed
protein was [95% pure as determined by colloidal Coo-
massie Brilliant Blue-stained SDS–PAGE gel.
Preparation and characterization of bio-NHS-TRAIL
and bio-ULS-TRAIL
We studied two different linkage strategies to introduce
biotin into His-TRAIL, by applying either a conventional
biotinylation reagent that reacts with primary amino groups
in the protein (biotin-NHS), or one that reacts to methio-
nine residues (biotin-ULS
TM
, ULS = universal linkage
system). Such an alternative strategy may prove less
harmful to the therapeutic activity of TRAIL, depending on
the extent to which side chain residues in the active
domains are modiﬁed. Biotin-ULS was provided by
Kreatech Biotechnology (Amsterdam, The Netherlands).
All syntheses were performed in a 10:1 molar ratio of
biotinylation reagent over TRAIL.
His-TRAIL in storage buffer was extensively dialyzed
against PBS containing 10% glycerol at 4C using Slide-
A-Lyzer dialysis cassettes (10,000 MWCO, Pierce) to
remove DTT and other components of the storage buffer
that can interfere in the reactions. Typically, the puriﬁed
His-TRAIL (500 ug, 7.6 nmol) at 0.7 mg/ml was mixed
either with Sulfo-NHS biotin (Pierce) (10 mg/ml in
DMF) or with biotin-ULS (10 mg/ml in 20 mM NaCl),
after which the mixtures were incubated for 4 h at 37C.
Unreacted biotinylation reagent was removed by dialy-
sis against PBS at 4C. The products were sterilized
by ﬁltration via disposable 0.2 lm ﬁlters and stored at
-20C.
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content using BCA protein assay (Pierce). The relative
number of coupled biotin molecules was determined by
anti-biotin ELISA. Wells were coated with serial dilutions
of the biotinylated proteins for 1 h at room temperature,
washed with PBS containing 0.05% Tween20 and incu-
bated for 1 h at room temperature with streptavidin-
peroxidase complex (Dako, 1:2500 in PBS), followed by a
standard incubation with OPD. The protein concentration
at which 50% of the maximum absorbance was measured
(EC50) was calculated by nonlinear regression (Graphpad
Prism), and used to calculate relative biotin:protein ratios
in each conjugate. The grade of biotinylation was further-
more assayed by MALDI-TOF analysis as described above
for RGDPEG-avidin.
Cells
Jurkat T cells were cultured in RPMI 1640 culture medium
(containing 25 mM HEPES and L-glutamine), supple-
mented with 10% heat-inactivated FCS (Bodinco,
Alkmaar, The Netherlands), 1 mM sodium pyruvate,
2m ML-glutamine, 0.5 mM 2-ME, and 0.1 mg/ml genta-
mycin sulfate obtained from BioWhittaker, and 0.02 lg/ml
fungizone. (Bristol-Meyers, Woerden, The Netherlands)
HUVEC were isolated by the UMCG Endothelial Cell
Facility by previously described methods [23]. Primary
isolates were cultured in 1% gelatin-coated tissue culture
ﬂasks (Corning, Costar, The Netherlands) at 37C under
5% CO2/95% air. The culture medium, hereafter referred to
as EC medium, consisted of RPMI 1640 (BioWhittaker,
Verviers, Belgium) supplemented with 20% heat inacti-
vated fetal calf serum (Integro, Zaandam, The
Netherlands), 2 mM L-glutamine (Invitrogen, Breda, The
Netherlands), 5 U/ml heparin (Leo Pharmaceutical Prod-
ucts, Weesp, The Netherlands), 100 U/ml penicillin
(Yamanouchi Pharma, Leiderdorp, The Netherlands,
100 lg/ml streptomycin (Radiumfarma-Fisiopharma,
Italy), and 50 lg/ml endothelial cell growth factor sup-
plement extracted from bovine brain. After attaining
conﬂuence, cells were detached from the surface by trypsin
EDTA (0.5/0.2 mg/ml in PBS) treatment and split in 1:3
ratio. Cells were used up to passage four.
Binding of RGDPEG-avidin to HUVEC
Binding afﬁnity of RGDPEG-avidin to avb3-integrin
expressed on the surface of HUVEC was determined by
competitive displacement of
125I-labeled Echistatin, which
is a known ligand for avb3 [24]. Conﬂuent monolayers of
HUVEC in 24-well plates (Costar) were incubated with
100,000 cpm
125I-Echistatin either in the presence of
excess of RGDPEG-avidin, free RGD-peptide or avidin as
competitors (competitors all in a concentration of 10 lM),
or a serial dilution of RGDPEG-avidin and free RGD-
peptide. Competition experiments were carried out with
divalent cation containing binding buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2,
1 mM MnCl2 and 1% BSA) at 4C for 4 h. Cells were
washed three times with binding buffer and lysed with 1 M
NaOH. Radioactivity was counted in a Packard RIASTAR
multiwell gamma counter (GMI, Minnesota, USA). Data
were analyzed by non-linear regression using the GraphPad
Prism program.
Complexation of biotinylated TRAIL
with RGDPEG-avidin
We studied the complexation of biotinylated TRAIL with
RGDPEG-avidin in an ELISA-like experimental setup.
Wells were coated with 50 ng of avidin or RGDPEG-avi-
din overnight at room temperature, blocked with BSA (1%
in PBS) and incubated with 10 ng of biotinylated TRAIL
for 2 h at room temperature. After the wells were washed
with PBS/0.05% Tween20, the amount of TRAIL associ-
ated with the avidin was detected by anti-TRAIL
immunodetection (anti-TRAIL antibody 2E5, Alexis,
Breda, The Netherlands) for 1 h, followed by standard
detection with GARPO/OPD.
Apoptotic activity of biotinylated TRAIL
The apoptosis inducing activity of the biotinylated products
was evaluated on Jurkat T cells and on endothelial cells,
using a cell viability assay and a caspase activity assay.
Experiments were conducted with the single cell types,
Jurkat tumor cells or HUVEC, or with a combination of
tumor and endothelial cells.
Assessment of TRAIL activity by MTS cell viability assay
Brieﬂy, cells were seeded in ﬂat-bottom 96-well plates at a
density of 3 9 10
4cells/well (Jurkat) or 1 9 10
4cells/well
(HUVEC) in 100 ll medium supplemented with the indi-
cated compounds. Concentrations of TRAIL, bio-NHS-
TRAIL and Bio-ULS-TRAIL ranging from 1 lg/ml to
1 ng/ml were tested on Jurkat. Only one concentration
(100 ng/ml) was tested on HUVEC. The MTS cell viability
assay (Promega) was performed after 48 h of incubation,
according to the manufacturer’s recommendations. Exper-
iments were performed in triplicate.
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We investigated the induction of apoptosis in Jurkat T cells
using a caspase 3/7 activity assay (Promega) employing
luminescence detection. Different experimental settings
were evaluated either reﬂecting direct incubation of the
products with tumor cells, or settings in which biotinylated
TRAIL was complexed to RGDPEG-avidin and/or
anchored onto endothelial cells.
First, we determined pro-apoptotic effects of non-com-
plexed TRAIL. About 5 9 10
3 Jurkat cells were incubated
with biotinylated TRAIL at a concentration of 100 ng/ml.
Experiments were carried in 96-well plates in 50 ll med-
ium supplemented with the indicated compounds for 4 h,
after which 50 ll of caspase 3/7 substrate was added to the
cells, followed by luminescence detection with a micro-
plate luminometer according to the provider’s instructions.
Next, we determined proapoptotic effects of RGDPEG-
avidin:TRAIL complexes in Jurkat cells. These experi-
ments were performed in the presence of endothelial cells,
to allow adherence of the RGD-equipped complexes to
avb3 integrin expressing cell layers. HUVEC were prein-
cubated with 10 lg/ml RGDPEG-avidin for 2 h at room
temperature after which the excess of non-cell associated
RGDPEG-avidin was removed by washing with PBS.
Control experiments included RGDPEG-avidin treated
HUVEC that were not washed and cells to which no
RGDPEG-avidin was added. All wells were supplemented
with biotinylated TRAIL (100 ng/ml in culture medium),
after which Jurkat cells (5 9 10
3 cells in 50 ll of medium)
were added. Cells were incubated for 4 h at 37C, after
which caspase activity was assayed as described above.
Experiments were conducted in triplicate.
Statistical analysis
Statistical analysis was performed using Student’s two-
tailed t-test, assuming equal variances. Difference were
considered to be signiﬁcant when P\0.05 unless other-
wise stated.
Results
Preparation and characterization of RGDPEG-avidin
We modiﬁed avidin with PEG-linked RGD-peptides to
obtain an avidin molecule which could bind to angiogenic
endothelial cells. Successful synthesis of RGDPEG-avidin
was proven by several analytical techniques. SDS-PAGE
analysis (Fig. 2a) showed a single band for avidin of
approximately 15 kDa, corresponding to the weight of one
of its four subunits. Different protein bands were observed
for RGDPEG-avidin with molecular weights corresponding
to the unmodiﬁed subunit and to subunits modiﬁed with
one or multiple RGDPEG moieties. Second, Western blot
of the product showed positive staining of these bands by
an anti-RGD-peptide antiserum. Due to the size heteroge-
neity of the PEG polymer, the RGD-band stained in a broad
streak rather than a discrete band (Fig. 2b). Of note, the
tetrameric band of avidin was not observed due to the
denaturating conditions of SDS-PAGE. Third, we analyzed
the product by MALDI-TOF mass spectrometry (Fig. 2c),
which showed peaks corresponding to avidin subunits
modiﬁed with RGDPEG to a different degree. From the
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Fig. 2 Characterization of RGDPEG-avidin. Panel A and B: SDS-
PAGE separation followed by CBB protein staining (a) or Western
blotting and anti-RGD detection (b). lane 1: MW marker, lane 2:
avidin, lane 3: RGDPEG-avidin. Unmodiﬁed avidin was separated
into its 15 kDa subunits, while RGDPEG-avidin was disassembled
into different bands corresponding to subunits with 0, 1, 2 or 3
attached RGDPEG groups. The intrinsic heterogeneity of PEG
polymers can be observed in the broadly stained band of the
RGDPEG-avidin Western blot. Panel C: MALDI-TOF analysis of
RGDPEG-avidin. Upper line: RGDPEG-avidin, bottom line: avidin.
During ionization, the tetrameric proteins have disassembled into
subunits, yielding a single peak for avidin and multiple peaks for
RGDPEG-avidin corresponding to modiﬁcation degree 0, 1, 2, 3, 4
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123average molecular weights (Mn) we calculated a relative
derivatization ratio of 1.4 RGDPEG groups per avidin
subunit, or a total of 5.6 RGDPEG groups per tetrameric
avidin.
Next, we investigated the interaction of RGDPEG-avi-
din with HUVEC, which express avb3-integrin when being
at a subconﬂuent state. To determine binding afﬁnity of
RGDPEG-avidin for avb3-integrin, we studied its capabil-
ity to compete with the avb3-integrin ligand
125I-echistatin.
While RGDPEG-avidin completely displaced
125I-echista-
tin from the cells, similar to the free RGD-peptide, avidin
did not affect binding of the radiolabeled peptide (Fig. 3a).
The sigmoid displacement curve with RGDPEG-avidin
(Fig. 3b) demonstrated a 2.9-fold increase in afﬁnity
(IC50 = 134 nM) as compared to the single RGD-peptide
(IC50 = 383 nM).
Preparation and characterization of biotinylated TRAIL
Since the modiﬁcation of side-chain residues may diminish
the activity of a therapeutic protein, we studied two dif-
ferent biotinylation strategies that target chemical
modiﬁcations at different amino acid residues, i.e., at lysine
groups (biotin-NHS) or methionine residues (biotin-ULS).
Such different labeling positions at the surface of the
protein may correlate to differences in pharmacological
activity of the biotinylated proteins. Anti-biotin ELISA
(Fig. 4a) demonstrated a higher biotin/TRAIL modiﬁcation
of biotin-NHS over biotin-ULS, which is in line with the
lower abundance of methionine residues as compared to
the number of lysine residues. We tried to conﬁrm these
data by analysis of the biotinylation extent by MALDI-
TOF mass spectrometry, which provided reliable data on
the average number of incorporated RGDPEG units in
avidin. Although this approach succeeded for biotin-NHS-
TRAIL (Fig. 4b), demonstrating the incorporation of about
1 biotin group per subunit of TRAIL, MALDI-TOF anal-
ysis failed to detect biotin-ULS modiﬁcation of TRAIL.
Most likely, the mass ionization step induced the dissoci-
ation of biotin-ULS from the protein. From the collective
results, we concluded that both strategies had yielded
biotinylated TRAIL with approximately 1–3 biotin groups
per protein (summarized in Table 1).
We studied complexation of biotinylated TRAIL with
RGDPEG-avidin that had been coated in 96-well plates.
Highest binding was observed for Bio-NHS-TRAIL,
probably due to its higher biotin content, while bio-ULS-
TRAIL showed approximately 40% less binding (Fig. 5).
Unmodiﬁed His-TRAIL showed non-speciﬁc binding to
RGDPEG-avidin as well, despite the absence of biotin
groups in this product. Non-speciﬁc binding of TRAIL to
RGDPEG-avidin was however far lower than binding to
unmodiﬁed avidin, most likely due to the PEGylation (data
not shown).
Cytotoxic and proapoptotic activity of TRAIL
complexes
To test whether our products were functionally active, i.e.,
capable of inducing cell death and apoptosis, we assessed
their activity on Jurkat T leukemic cells and HUVEC
endothelial cells. Figure 6a shows the dose-dependent
cytotoxiceffectsatJurkatcellsaftertreatmentfor48 h.Both
His-TRAIL, Bio-NHS-TRAIL and Bio-ULS-TRAIL effec-
tively killed Jurkat cells with IC50 values between 40 ng/ml
and 123 ng/ml (Table 1). While the Bio-NHS modiﬁcation
resulted in a considerable reduction in activity compared to
the unmodiﬁed protein, Bio-ULS-TRAIL displayed almost
similar activity as unmodiﬁed TRAIL. The pro-apoptotic
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Fig. 3 Association of RGDPEG-avidin with endothelial cells. Sub-
conﬂuent HUVEC were incubated with radiolabeled echistatin, which
is a known ligand for avb3 integrin, and RGDPEG-avidin, free
RGDpeptide or unmodiﬁed avidin. Panel A: Binding speciﬁcity.
Echistatin was displaced by excess of RGDPEG-avidin or free RGD-
peptide (both at 10 lM) but not by excess of avidin. *P\0.05. Panel
B: Afﬁnity of binding. Echistatin binding was displaced by different
concentrations of the added competing ligands, showing the increased
afﬁnity of RGPEG-avidin over the single RGDpeptide ligand
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123activity of His-TRAIL and biotinylated TRAIL derivatives
in Jurkat cells was furthermore determined by analyzing
caspase 3/7activity,asshowninFig. 6b.These experiments
conﬁrmed the relative higher activity of bio-ULS-TRAIL
versus bio-NHS-TRAIL, and the absence of caspase induc-
tion by RGDPEG-avidin (data not shown). In contrast to
Jurkat cells, no cytotoxic effects were observed when HU-
VEC were incubated with the products (Fig. 6c).
Finally, we investigated the proapoptotic effects of
RGDPEG-avidin:TRAIL complexes in Jurkat cells. These
experiments were performed in the presence of endothelial
cells, to allow adherence of the RGD-equipped complexes
to avb3 integrin expressing cell layers. First, we determined
the effects of avidin:TRAIL complexes formed in the
presence of an excess of RGDPEG-avidin. As can be
observed in Fig. 7, such complexes with both types of
biotinylated TRAIL showed similar activity to the non-
complexed biotinylated TRAIL derivatives (striped bars
versus white bars, respectively). Furthermore, in agreement
with Fig. 6b, Bio-NHS-TRAIL showed a reduced activity
as compared to unmodiﬁed TRAIL, while Bio-ULS-
TRAIL retained its activity.
A striking result was observed when the excess of
RGDPEG-avidin was removed before addition of TRAIL
and Jurkat cells, leaving only endothelial-associated
RGDPEG-avidin available for complexation with biotin-
ylated TRAIL. This procedure signiﬁcantly potentiated the
proapoptotic effect for both Bio-NHS-TRAIL and Bio-
ULS-TRAIL, the latter even beyond the activity of
unmodiﬁed TRAIL.
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Fig. 4 Characterization of biotinylated TRAILs. Panel A: Anti-biotin
ELISA with streptavidin-HRP. Signals were corrected for background
and expressed relative to the maximum detected intensity. Panel B:
MALDI-TOF analysis of TRAIL and biotin-NHS-TRAIL
Table 1 Characteristics of biotinylated TRAIL variants
Relative biotin content
(Biotin/TRAIL)
a
Activity in cell viability
assay (IC50 in ng/ml)
b
Activity in caspase
3/7 assay
c (%)
TRAIL – 40 100
Bio-NHS-TRAIL 1.6 123 35
Bio-ULS-TRAIL 0.8 60 126
a Expressed as mole biotin bound per mole of trimeric TRAIL. Relative biotin content was determined by MALDI-TOF analysis (bio-NHS-
TRAIL) or ELISA (BIO-ULS-TRAIL)
b As determined after 48 h of incubation with Jurkat cells
c As determined after 4 h of incubation at 10 ng/ml with Jurkat cells
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Fig. 5 Association of biotinylated TRAIL with RGDPEG-avidin. 96-
well plates were coated overnight with 50 ng RGDPEG-avidin and
incubated with indicated compounds for 2 h. TRAIL binding was
assessed by anti-TRAIL immunodetection and expressed relative to
the highest signal obtained with biotin-NHS-TRAIL. Experiments
were performed in triplicate
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In the present study we describe the development and
functional evaluation of RGD-avidin:TRAIL complexes.
These targeted complexes of TRAIL showed enhanced
binding to endothelial cells and maintained their pro-
apoptotic activity. As a result of the binding to angiogenic
endothelial cells of these complexes, an improved tumor
accumulation and enhanced residence within tumor tissue
can be expected. Such an improvement in the pharmaco-
kinetic proﬁle of TRAIL may further enhance its
therapeutic efﬁcacy and enable a reduction in dosing
frequency.
avb3 integrin is a validated target for drug delivery and
imaging approaches directed to angiogenic endothelium.
One of the most popular ligands for avb3 integrin is the
cyclic RGD-peptide cyclo(RGDfK). Due to the special
constrained conformation of the cyclic RGD-peptide and
the D-phenylalanine amino acid, its binding motif adopts a
high afﬁnity conformation for av-integrins [25]. The
cyclo(RGDfK) peptide has been used successfully for the
delivery of a wide range of drug or gene carrying systems
(e.g., liposomes, polymers, adenoviruses) [18]. Since the
cyclopeptide is an unnatural peptide, it can not be encoded
by a DNA sequence and requires chemical synthesis and
hence chemical coupling techniques to prepare multivalent
targeting devices. The present paper describes a versatile
approach in which multivalent RGD-avidin is complexed
with biotinylated TRAIL. The RGD-peptides are linked to
avidin via bifunctional PEG linkers, thereby surrounding
the avidin by a hydrophilic PEG shell tethered with tar-
geting ligands. PEGylation is a widely accepted
methodology for improvement of therapeutic proteins, and
affects both the immunological properties as well as the
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Fig. 6 TRAIL activity assays. Panel A: Cell viability of Jurkat T
cells after 48 h of incubation with indicated compounds. Cell viability
was assessed by MTS assay. Experiments were performed in
triplicate. Panel B: Caspase 3/7 activity in Jurkat T cells after 4 h
of incubation with 100 ng/ml of the indicated TRAIL derivatives.
RLU: relative light units. Panel C: Cell viability (MTS assay) of
HUVEC after 48 h of incubation with 100 ng/ml of indicated
compounds
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Fig. 7 Proapoptotic activity of RGDPEG-avidin:TRAIL complexes.
Assays were performed in 96-well plates seeded with HUVEC that
were subsequently incubated at room temperature with RGDPEG-
avidin (10 lg/ml) and biotinylated TRAIL (100 ng/ml), to allow
assembly of the complexes. Next, Jurkat T cells were added followed
by 4 h of incubation at 37C, after which the activation of caspase 3/7
was determined by a luminescence based assay. Experiments were
carried out in the absence of RGDPEG-avidin (control experiment,
white bars), inthe presence ofexcessof RGDPEG-avidin (striped bars,
100-fold molar excess over biotinylated TRAIL) or in wells incubated
with RGDPEG-avidin that had been washed before addition of biotin-
TRAIL and Jurkat cells (black bars). *P\0.05 versus TRAIL;
#P\0.05 versus biotin-TRAIL in the absence of RGDPEG-avidin
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123renal ﬁltration of proteins [26]. The functionalization of
avidin with RGD-PEG groups thus will combine several
advantageous properties. RGDPEG-avidin displayed
nanomolar afﬁnity for avb3 integrin expressing endothelial
cells, which is in good agreement with the data obtained
with other RGD-equipped proteins prepared in our group
[27].
We have compared two different biotinylation proce-
dures, which react at different amino acid side chain
residues. While biotin-NHS couples at lysine residues,
biotin-ULS binds at methionines residues in TRAIL. The
methionines in TRAIL are not solvent exposed, as can be
derived from the crystal structure of TRAIL [28]. There-
fore, the most likely binding site for biotin-ULS is the
methionine in the HIS-tag of the recombinant protein. In
contrast, most lysine residues are readily accessible,
including ones at positions that will interface with the
Death receptor. This could explain why Biotin-ULS-
TRAIL better maintained its proapoptotic activity than
biotin-NHS derivatized TRAIL. Whether the greater loss in
activity of biotin-NHS-TRAIL is due to the relative higher
extent of derivatization or to modiﬁcations of lysine resi-
dues in the activity domains of protein can not be
concluded from our data.
Upon complexation of biotinylated TRAIL with RGD-
PEG-avidin, a bulky structure has been introduced onto the
surface of the therapeutic protein. The assembled com-
plexes, however, fully maintained their TRAIL activity
indicating that steric hindrance did not interfere in the
TRAIL-death receptor ligation. Figure 7 showed similar
proapoptotic activities for either biotinylated TRAIL or the
complexes formed in the presence of excess of RGDPEG-
avidin. Remarkably, we observed an enhancement of cas-
pase activity when the excess of RGDPEG-avidin was
removed, leaving only surface-exposed RGDPEG-avidin at
the endothelial cell layer. One of the explanations that
may account for this is the assembly of multiple TRAIL
molecules onto a single avidin, thereby affording a
‘mega’TRAIL complex with enhanced death-inducing
activity, as was also observed for multimeric forms of
Fas-ligand [29]. Such types of complexes would facilitate
the close assembly of multiple death receptors, thereby
potentiating the induction of death signaling. The presence
of an excess of RGDPEG-avidin would avoid the formation
of such complexes, as both components were added in a
100:1 molar ratio of avidin:TRAIL. Gently washing of the
endothelial cells after RGDPEG-avidin incubation
removed the excess of unbound RGDPEG-avidin, leaving
only cell-associated avidin after incubation at room term-
perature. These conditions therefore provided an excess of
biotinylated TRAIL over avidin, now favoring the forma-
tion of multimeric TRAIL complexes. Alternatively, the
exposure of TRAIL via RGD-PEG-avidin onto the surface
of endothelial cells may explain its increased activity, as
has been observed for chimeric TRAIL variants directed to
tumor receptors [10].
HUVEC were not killed by TRAIL or its derivatives, as
has been described by others [30]. On the other hand,
although TRAIL does not induce apoptosis in endothelial
cells, it activates other processes such as production of NO
and reactive oxygen species which may alter the tumor
responsiveness to TRAIL [31]. This can not explain the
results shown in Fig. 7, since endothelial cells were pre-
incubated with RGDPEG-avidin only and preincubations
were performed at room temperature rather than at 37C.
Such effects of RGD-equipped TRAIL may occur however
in vivo. In addition, tumor derived growth factors might
sensitize endothelial cells to TRAIL’s apoptosis inducing
capacity, similar to the ﬁndings reported for TNF-
sensitivity [32].
The complexation of biotinylated TRAIL with RGD-
PEG-avidin and its association with angiogenic endothelial
cells may afford an increased accumulation into the tumor
blood vessels, similar to the enhanced tumor accumulation
of other RGD-modiﬁed proteins [18]. An unresolved issue
is whether RGD-avidin/TRAIL complexes bound to the
tumor vasculature can interact with tumor cells behind the
endothelial lining in vivo. To interact with tumor cells and
induce tumor apoptosis, TRAIL complexes bound to the
tumor vasculature should dissociate and penetrate into the
tumor tissue. Several considerations may be important in
this respect, such as the expression of avb3 integrin on both
luminal and abluminal side of the endothelium and the fact
that many tumor cells express avb3 integrin [18]. Both of
these will favor the interaction of RGD-avidin complexed
TRAIL with tumor cells. Furthermore, RGD-avidin bind-
ing to endothelial cells is less tight than the typical
antibody binding. This may favor redistribution of the
complexes upon their initial binding to avb3 integrin.
Homing to the tumor vasculature will provide elevated
concentrations within the tumor microenvironment, which
may subsequently provide elevated intratumoral concen-
trations. Together with the observed enhancement of
TRAIL activity, this may favor a more efﬁcient induction
of apoptosis in tumor cells.
To summarize, we have prepared a novel type of RGD-
targeted TRAIL with binding speciﬁcity for angiogenic
endothelium and maintenance of strong cytotoxic activity.
Whether in vivo application of this product will lead to an
enhanced tumor accumulation still needs to be investi-
gated. We now succeeded in coupling the well known
homing device RGD to the TRAIL molecule, without
losing the apoptosis-inducing activity of TRAIL or the
receptor-binding properties of RDG peptides. An enhanced
activity could even be demonstrated in vitro. This may, in
combination with an improved pharmacokinetic proﬁle
Apoptosis (2008) 13:225–235 233
123induced by the PEG and RGD moieties, lead to improved
effects of TRAIL in vivo. Lastly, the followed synthetic
approach offers opportunities for the complexation with
alternative targeting ligands that bind directly to tumor
cells, such as tumor-speciﬁc antibodies or peptide ligands.
Acknowledgments S. Muskee, H. Permentier, H.E. Moorlag and
J. Dokter are kindly acknowledged for assistance in experiments.
Colleagues at Kreatech are acknowledged for scientiﬁc discussions
and critical reading of the manuscript. This work was made possible
by grants from the Marie Curie fellowship program of the European
Community (HPMI-CT-2002-00218) and of the SenterNovem agency
of the Dutch Ministry of Economic Affairs (TSGE1083).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Wajant H, Gerspach J, Pﬁzenmaier K (2005) Tumor therapeutics
by design: targeting and activation of death receptors. Cytokine
Growth Factor Rev 16:55–76
2. Kelley SK, Ashkenazi A (2004) Targeting death receptors in
cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4:333–339
3. Duiker EW, Mom CH, de Jong S et al (2006) The clinical trail of
TRAIL. Eur J Cancer 42:2233–2240
4. Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor
activity of recombinant soluble Apo2 ligand. J Clin Invest
104:155–162
5. Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity
of tumor necrosis factor-related apoptosis-inducing ligand in
vivo. Nat Med 5:157–163
6. Muhlenbeck F, Schneider P, Bodmer JL et al (2000) The tumor
necrosis factor-related apoptosis-inducing ligand receptors
TRAIL-R1 and TRAIL-R2 have distinct cross-linking require-
ments for initiation of apoptosis and are non-redundant in JNK
activation. J Biol Chem 275:32208–32213
7. Kelley RF, Totpal K, Lindstrom SH et al (2005) Receptor-
selective mutants of apoptosis-inducing ligand 2/tumor necrosis
factor-related apoptosis-inducing ligand reveal a greater contri-
bution of death receptor (DR) 5 than DR4 to apoptosis signaling.
J Biol Chem 280:2205–2212
8. van der Sloot AM, Tur V, Szegezdi E et al (2006) Designed
tumor necrosis factor-related apoptosis-inducing ligand variants
initiating apoptosis exclusively via the DR5 receptor. Proc Natl
Acad Sci USA 103:8634–8639
9. Bremer E, Samplonius DF, Peipp M et al (2005) Target cell-
restricted apoptosis induction of acute leukemic T cells by a
recombinant tumor necrosis factor-related apoptosis-inducing
ligand fusion protein with speciﬁcity for human CD7. Cancer Res
65:3380–3388
10. Bremer E, Samplonius DF, van Genne L et al (2005) Simulta-
neous inhibition of epidermal growth factor receptor (EGFR)
signaling and enhanced activation of tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) receptor-mediated
apoptosis induction by an scFv:sTRAIL fusion protein with
speciﬁcity for human EGFR. J Biol Chem 280:10025–10033
11. Bremer E, Samplonius D, Kroesen BJ et al (2004) Exceptionally
potent anti-tumor bystander activity of an scFv:sTRAIL fusion
protein with speciﬁcity for EGP2 toward target antigen-negative
tumor cells. Neoplasia 6:636–645
12. Lyu MA, Rosenblum MG (2005) The immunocytokine scFv23/
TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to
tumor necrosis factor (TNF) via up-regulation of TNF receptor-1.
Mol Cancer Ther 4:1205–1213
13. Liu Y, Zhang W, Cheung LH et al (2006) The antimelanoma
immunocytokine scFvMEL/TNF shows reduced toxicity and
potent antitumor activity against human tumor xenografts. Neo-
plasia 8:384–393
14. Liu Y, Cheung LH, Hittelman WN, Rosenblum MG (2003)
Targeted delivery of human pro-apoptotic enzymes to tumor
cells: In vitro studies describing a novel class of recombinant
highly cytotoxic agents. Mol Cancer Ther 2:1341–1350
15. Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A (2004)
Coupling tumor necrosis factor-alpha with alphaV integrin
ligands improves its antineoplastic activity. Cancer Res 64:
565–571
16. Gasparri A, Moro M, Curnis F et al (1999) Tumor pretargeting
with avidin improves the therapeutic index of biotinylated tumor
necrosis factor alpha in mouse models. Cancer Res 59:2917–2923
17. Magni F, Curnis F, Marazzini L et al (2001) Biotinylation sites of
tumornecrosisfactor-alphadeterminedbyliquidchromatography-
mass spectrometry. Anal Biochem 298:181–188
18. Temming K, Schiffelers RM, Molema G, Kok RJ (2005) RGD-
based strategies for selective delivery of therapeutics and imaging
agents to the tumour vasculature. Drug Resist Updat 8:381–402
19. Caliceti P, Chinol M, Roldo M et al (2002) Poly(ethylene glycol)-
avidin bioconjugates: suitable candidates for tumor pretargeting.
J Control Release 83:97–108
20. Kok RJ, Schraa AJ, Bos EJ et al (2002) Preparation and func-
tional evaluation of RGD-modiﬁed proteins as alpha(v)beta(3)
integrin directed therapeutics. Bioconjug Chem 13:128–135
21. Temming K, Lacombe M, van der Hoeven P et al (2006) Delivery
of the p38 MAPkinase inhibitor SB202190 to angiogenic endo-
thelial cells: development of novel RGD-equipped and
PEGylated drug-albumin conjugates using platinum(II)-based
drug linker technology. Bioconjug Chem 17:1246–1255
22. van der Sloot AM, Mullally MM, Fernandez-Ballester G, Serrano
L, Quax WJ (2004) Stabilization of TRAIL, an all-beta-sheet
multimeric protein, using computational redesign. Protein Eng
Des Sel 17:673–680
23. Mulder AB, Blom NR, Smit JW et al (1995) Basal tissue factor
expression in endothelial cell cultures is caused by contaminating
smooth muscle cells. Reduction by using chymotrypsin instead of
collagenase. Thromb Res 80:399–411
24. Kumar CC, Nie H, Rogers CP et al (1997) Biochemical charac-
terization of the binding of echistatin to integrin alphavbeta3
receptor. J Pharmacol Exp Ther 283:843–853
25. Marinelli L, Lavecchia A, Gottschalk KE, Novellino E, Kessler H
(2003) Docking studies on alphavbeta3 integrin ligands: phar-
macophore reﬁnement and implications for drug design. J Med
Chem 46:4393–4404
26. Salmaso S, Semenzato A, Bersania S et al (2005) Preparation and
characterization of active site protected poly(ethylene glycol)-
avidin bioconjugates. Biochim Biophys Acta 1726:57–66
27. Temming K, Lacombe M, Schaapveld RQ et al (2006) Rational
design of RGD-albumin conjugates for targeted delivery of the
VEGF-R kinase inhibitor PTK787 to angiogenic endothelium.
Chem Med Chem 1:1200–1203
28. Cha SS, Sung BJ, Kim YA et al (2000) Crystal structure of
TRAIL-DR5 complex identiﬁes a critical role of the unique frame
insertion in conferring recognition speciﬁcity. J Biol Chem
275:31171–31177
29. Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H
(2007) A novel multimeric form of FasL modulates the ability of
234 Apoptosis (2008) 13:225–235
123diabetogenic T cells to mediate type 1 diabetes in an adoptive
transfer model. Mol Immunol 44:2884–2892
30. Zauli G, Secchiero P (2006) The role of the TRAIL/TRAIL
receptors system in hematopoiesis and endothelial cell biology.
Cytokine Growth Factor Rev 17:245–257
31. Di Pietro R, Mariggio MA, Guarnieri S et al (2006) Tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)
regulates endothelial nitric oxide synthase (eNOS) activity and its
localization within the human vein endothelial cells (HUVEC) in
culture. J Cell Biochem 97:782–794
32. Kuroda K, Miyata K, Tsutsumi Y et al (2000) Preferential
activity of wild-type and mutant tumor necrosis factor-alpha
against tumor-derived endothelial-like cells. Jpn J Cancer Res
91:59–67
Apoptosis (2008) 13:225–235 235
123